Does Syndax ( SNDX ) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Syndax ( SNDX ) Q2 Revenue Jumps 986%
Syndax Pharmaceuticals ( NASDAQ:SNDX ) , a biopharmaceutical company specializing in oncology therapeutics, reported its second-quarter 2025 earnings on August 4, 2025. The most notable news was its substantial GAAP revenue growth, driven primarily by commercial traction for its newly launched ...
Syndax Pharmaceuticals ( SNDX ) Reports Q2 Loss, Beats Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Syndax ( SNDX ) Rating Upgrade to Buy
Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Earnings Preview: Jazz Pharmaceuticals ( JAZZ ) Q2 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 237.83% Upside in Syndax ( SNDX ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, ...
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
- Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients ...
Syndax Presents New Revuforj® ( revumenib ) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
- 26% ( 20/77 ) CR+CRh rate and 48% ( 37/77 ) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population ...
Syndax Announces Participation in June Investor Conferences - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
Syndax Announces Participation in June Investor Conferences
NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, ...
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday - Amer Sports ( NYSE:AS ) , Agilysys ( NASDAQ:AGYS )
U.S. stocks were lower, with the Nasdaq Composite falling more than 50 points on Tuesday. Shares of Agilysys, Inc. AGYS rose sharply during Tuesday's session following better-than-expected fourth-quarter results.
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® ( revumenib ) and Niktimvo™ ( axatilimab-csfr )
- Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and ...
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® ( revumenib ) and Niktimvo™ ( axatilimab-csfr ) - Syndax Pharmaceuticals ( NASDAQ:SNDX )
- Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r - - Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with ...
Wall Street Analysts See a 219.98% Upside in Syndax ( SNDX ) : Can the Stock Really Move This High?
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Syndax Pharmaceuticals ( SNDX ) Reports Q1 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 5.77% and 36.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
NEW YORK, May 02, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to ...
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
CAMBRIDGE, Mass., May 01, 2025 ( GLOBE NEWSWIRE ) -- Foghorn® Therapeutics Inc. ( Nasdaq: FHTX ) , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., ...
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - AstraZeneca ( NASDAQ:AZN ) , BP ( NYSE:BP )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday. Shares of NXP Semiconductors N.V. NXPI fell sharply in today's pre-market trading after the company reported first-quarter financial results and issued second-quarter EPS guidance with its ...
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Algoma Steel Group ( NASDAQ:ASTL ) , AGM Gr Hldgs ( NASDAQ:AGMH )
Shares of Leggett & Platt, Incorporated LEG rose sharply in pre-market trading after the company reported better-than-expected first-quarter EPS results and raised its FY25 EPS guidance. Leggett & Platt reported quarterly earnings of 24 cents per share which beat the analyst consensus estimate of ...
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, April 28, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, ...
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
NEW YORK, April 04, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares ...
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, April 02, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth - Syndax Pharmaceuticals ( NASDAQ:SNDX )
Revuforj generated $7.7 million in net revenue within its first five weeks on the market. JPMorgan estimates Revuforj's 2025 U.S. sales to reach $50 million, driven by KMT2A use. Feel unsure about the market's next move?
Syndax Pharmaceuticals ( SNDX ) Reports Q4 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- $7.7 million in Revuforj® ( revumenib ) net product revenue in initial five weeks of launch ...
Syndax Announces Participation in March Investor Conferences - Syndax Pharmaceuticals ( NASDAQ:SNDX )
WALTHAM, Mass., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals SNDX, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.
Syndax Announces Participation in March Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the ...
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
WALTHAM, Mass., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and ...
Royalty Pharma Reports Q4 and Full Year 2024 Results
NEW YORK, Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts.
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - Syndax Pharmaceuticals ( NASDAQ:SNDX )
NEW YORK, Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Syndax Pharmaceuticals, Inc. SNDX breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally. Royalty Pharma ( NASDAQ: RPRX ) , W.P. Carey ( NYSE: WPC ) , and Omega Healthcare Investors ( NYSE: OHI ) are three dividend payers with stock prices that have fallen recently.At ...
Why Is Incyte ( INCY ) Up 2.1% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Revuforj® ( revumenib )
LOUISVILLE, Ky., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Syndax Pharmaceuticals for Revuforj® ( revumenib ) , as the first and only menin inhibitor approved for the treatment of ...
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday - Roku ( NASDAQ:ROKU )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham boosted the price target for Coinbase Global, Inc. COIN from $290 to $375.
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
NVAX and RNA are in the spotlight following Q3 results and study data, respectively.
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - Syndax Pharmaceuticals ( NASDAQ:SNDX )
On Tuesday, Syndax Pharmaceuticals Inc SNDX revealed topline results from the relapsed or refractory ( R/R ) mutant NPM1 ( mNPM1 ) acute myeloid leukemia ( AML ) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields - Johnson & Johnson ( NYSE:JNJ )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Syndax Pharmaceuticals ( SNDX ) Reports Q3 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - Royalty Pharma ( NASDAQ:RPRX ) , Syndax Pharmaceuticals ( NASDAQ:SNDX )
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib Expected to fund Syndax through profitability; proforma cash approaching $800 million as of June 30
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sempra ( NYSE:SRE )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. analyst Scott Buck initiated coverage on WidePoint Corporation WYY with a Buy rating ...
